Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.

Wang B, Studdert DM, Sarpatwari A, Franklin JM, Landon J, Kesselheim AS.

PLoS One. 2017 Apr 7;12(4):e0175313. doi: 10.1371/journal.pone.0175313. eCollection 2017.

2.

Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.

Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST.

Otolaryngol Head Neck Surg. 2017 Apr;156(4):683-692. doi: 10.1177/0194599816689666. Epub 2017 Jan 24.

PMID:
28116974
3.

Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014.

Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST.

Otolaryngol Head Neck Surg. 2017 Feb;156(2):285-288. doi: 10.1177/0194599816684094. Epub 2017 Jan 17.

PMID:
28093943
4.

Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results.

Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS.

JAMA Intern Med. 2016 Dec 1;176(12):1826-1833. doi: 10.1001/jamainternmed.2016.6008.

PMID:
27723879
5.

Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.

Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS.

PLoS One. 2016 Mar 31;11(3):e0152195. doi: 10.1371/journal.pone.0152195. eCollection 2016.

6.

Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?

Wang B, Kesselheim AS.

JAMA. 2016 Mar 1;315(9):857-8. doi: 10.1001/jama.2016.1149. No abstract available.

PMID:
26934246
8.

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.

Kesselheim AS, Wang B, Franklin JM, Darrow JJ.

BMJ. 2015 Sep 23;351:h4633. doi: 10.1136/bmj.h4633.

9.

Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.

Wang B, Choudhry NK, Gagne JJ, Landon J, Kesselheim AS.

Am Heart J. 2015 Mar;169(3):379-386.e1. doi: 10.1016/j.ahj.2014.12.014. Epub 2015 Jan 7.

PMID:
25728728
10.

Variations in time of market exclusivity among top-selling prescription drugs in the United States.

Wang B, Liu J, Kesselheim AS.

JAMA Intern Med. 2015 Apr;175(4):635-7. doi: 10.1001/jamainternmed.2014.7968. No abstract available.

PMID:
25664700
11.

Chemotherapy parity laws: a remedy for high drug costs?

Wang B, Joffe S, Kesselheim AS.

JAMA Intern Med. 2014 Nov;174(11):1721-2. doi: 10.1001/jamainternmed.2014.4878. No abstract available.

PMID:
25243936
12.

The role of direct-to-consumer pharmaceutical advertising in patient consumerism.

Wang B, Kesselheim AS.

Virtual Mentor. 2013 Nov 1;15(11):960-5. doi: 10.1001/virtualmentor.2013.15.11.pfor1-1311. No abstract available.

13.

Clinical and regulatory features of drugs not initially approved by the FDA.

Wang B, Avorn J, Kesselheim AS.

Clin Pharmacol Ther. 2013 Dec;94(6):670-7. doi: 10.1038/clpt.2013.165. Epub 2013 Aug 20. Review.

PMID:
23963252
14.

Defining "innovativeness" in drug development: a systematic review.

Kesselheim AS, Wang B, Avorn J.

Clin Pharmacol Ther. 2013 Sep;94(3):336-48. doi: 10.1038/clpt.2013.115. Epub 2013 May 30. Review.

PMID:
23722626
15.

Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.

Kesselheim AS, Wang B, Studdert DM, Avorn J.

PLoS Med. 2012;9(8):e1001280. doi: 10.1371/journal.pmed.1001280. Epub 2012 Aug 7.

Supplemental Content

Loading ...
Support Center